[go: up one dir, main page]

WO1996002553A3 - AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES - Google Patents

AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES Download PDF

Info

Publication number
WO1996002553A3
WO1996002553A3 PCT/EP1995/002837 EP9502837W WO9602553A3 WO 1996002553 A3 WO1996002553 A3 WO 1996002553A3 EP 9502837 W EP9502837 W EP 9502837W WO 9602553 A3 WO9602553 A3 WO 9602553A3
Authority
WO
WIPO (PCT)
Prior art keywords
6alkyl
amino purine
oxopyrrolidin
piperidin
solvates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1995/002837
Other languages
French (fr)
Other versions
WO1996002553B1 (en
WO1996002553A2 (en
Inventor
Barry Edward Di Ayres
Michael Gregson
George Blanch Ewan
Suzanne Elaine Keeling
Richard Bell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Priority to AU36982/95A priority Critical patent/AU3698295A/en
Publication of WO1996002553A2 publication Critical patent/WO1996002553A2/en
Publication of WO1996002553A3 publication Critical patent/WO1996002553A3/en
Publication of WO1996002553B1 publication Critical patent/WO1996002553B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Amino purine-β-D-ribofuranuronamide derivatives are described having general formula (I) and salts and solvates thereof, wherein: R1 is hydrogen, C¿3-8?cycloaklyl or C1-6alkyl; A represents O, S, SO, SO2, a saturated hydrocarbon moiety having from 1 to 4 carbon atoms or an unsaturated hydrocarbon moiety having from 2 to 4 carbon atoms; R?2¿ is C¿3-8?cycloalkyl, C3-8cycloalkyl C1-6alkyl, Alk1Y, -(CHR?5)¿m (Alk2)nZ or appropriately substituted C3-8cycloalkyl, C3-8cycloalkylC1-6alkyl, pyrrolidin-3-yl, 2-oxopyrrolidin-4-yl, 2-oxopyrrolidin-5-yl, piperidin-3-yl or piperidin-4-yl, and Q is oxygen or sulphur with the proviso that when A represents O, S, SO or SO2, Alk1 represents a C2-6alkylene group. Compounds of formula (I) and their salts and solvates have use in medicine as anti-inflammatory agents, particularly in the treatment of patients with inflammatory conditions who are susceptible to leukocyte-induced tissue damage.
PCT/EP1995/002837 1994-07-14 1995-07-14 AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES Ceased WO1996002553A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU36982/95A AU3698295A (en) 1994-07-14 1995-07-14 Amino purine-beta -d-ribofuranuronamide derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9414193.4 1994-07-14
GB9414193A GB9414193D0 (en) 1994-07-14 1994-07-14 Compounds

Publications (3)

Publication Number Publication Date
WO1996002553A2 WO1996002553A2 (en) 1996-02-01
WO1996002553A3 true WO1996002553A3 (en) 1996-03-07
WO1996002553B1 WO1996002553B1 (en) 1996-03-28

Family

ID=10758311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1995/002837 Ceased WO1996002553A2 (en) 1994-07-14 1995-07-14 AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES

Country Status (5)

Country Link
AU (1) AU3698295A (en)
GB (1) GB9414193D0 (en)
IL (1) IL114578A0 (en)
WO (1) WO1996002553A2 (en)
ZA (1) ZA955784B (en)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW528755B (en) * 1996-12-24 2003-04-21 Glaxo Group Ltd 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
YU44900A (en) * 1998-01-31 2003-01-31 Glaxo Group Limited 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
PE20000270A1 (en) * 1998-02-14 2000-05-20 Glaxo Group Ltd DERIVATIVES OF 2- (PURIN-9-IL) -TETRAHIDROFURAN-3,4-DIOL
GB9813540D0 (en) * 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
GB9813535D0 (en) 1998-06-23 1998-08-19 Glaxo Group Ltd Chemical compounds
TR200100410T2 (en) 1998-06-23 2001-06-21 Glaxo Group Limited 2- (purin-9-yl) -tetrahydrofuran-3,4-diol derivatives.
WO2000002861A1 (en) 1998-07-10 2000-01-20 The United States Of America, Represented By Secretary, Department Of Health And Human Services A3 adenosine receptor antagonists
US7378400B2 (en) 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
AU3091301A (en) 2000-01-14 2001-07-24 Us Health Methanocarba cycloalkyl nucleoside analogues
US20010051612A1 (en) * 2000-02-23 2001-12-13 Gloria Cristalli 2-Thioether A2A receptor agonists
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
NZ545787A (en) 2001-10-01 2007-12-21 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
AR044519A1 (en) 2003-05-02 2005-09-14 Novartis Ag DERIVATIVES OF PIRIDIN-TIAZOL AMINA AND PIRIMIDIN-TIAZOL AMINA
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (en) 2004-05-24 2006-07-26 Glaxo Group Ltd PURINA DERIVATIVES
US7423144B2 (en) 2004-05-26 2008-09-09 Inotek Pharmaceuticals Corporation Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
US7605143B2 (en) 2004-08-02 2009-10-20 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity
US7442687B2 (en) 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
US7576069B2 (en) 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
BRPI0515506A (en) 2004-09-20 2008-07-29 Inotek Pharmaceuticals Corp purine derivatives and methods of use thereof
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
KR20130020850A (en) 2005-10-21 2013-02-28 노파르티스 아게 Human antibodies against il-13 and therapeutic uses
AU2006320578B2 (en) 2005-11-30 2013-01-31 Inotek Pharmaceuticals Corporation Purine derivatives and methods of use thereof
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AR060607A1 (en) 2006-04-21 2008-07-02 Novartis Ag PURINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION METHOD AND USES IN OBSTRUCTIVE OR INFLAMMATORY DISEASES OF RESPIRATORY ROADS.
WO2008037477A1 (en) 2006-09-29 2008-04-03 Novartis Ag Pyrazolopyrimidines as p13k lipid kinase inhibitors
CN101522682A (en) 2006-10-30 2009-09-02 诺瓦提斯公司 Heterocyclic compounds as anti-inflammatory agents
WO2009006089A2 (en) * 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services A2 adenosine receptor agonists
PL2231642T3 (en) 2008-01-11 2014-04-30 Novartis Ag Pyrimidines as kinase inhibitors
US20110281917A1 (en) 2009-01-29 2011-11-17 Darrin Stuart Substituted Benzimidazoles for the Treatment of Astrocytomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (en) 2009-08-12 2015-09-24 ノバルティス アーゲー Heterocyclic hydrazone compounds and their use for the treatment of cancer and inflammation
TR201900259T4 (en) 2009-08-17 2019-02-21 Intellikine Llc Heterocyclic Compounds and Their Uses
AU2010284972A1 (en) 2009-08-20 2012-03-08 Novartis Ag Heterocyclic oxime compounds
US8518957B2 (en) 2009-12-02 2013-08-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methanocarba adenosine derivatives, pharmaceutical compositions, and method of reducing intraocular pressure
DK2523669T3 (en) 2010-01-11 2017-02-06 Inotek Pharmaceuticals Corp COMBINATION, KIT AND PROCEDURE TO REDUCE INTRAOCULAR PRESSURE
KR20130029050A (en) 2010-03-26 2013-03-21 이노텍 파마슈티컬스 코포레이션 Method of reducing intraocular pressure in humans using n6-cyclopentyladenosine(cpa), cpa derivatives or prodrugs thereof
UY33597A (en) 2010-09-09 2012-04-30 Irm Llc COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE TRK
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (en) 2011-02-23 2015-11-10 インテリカイン， エルエルシー Heterocyclic compounds and uses thereof
PH12013501758A1 (en) 2011-02-25 2013-10-14 Irm Llc Pyrazolo [1,5-a] pyridines as trk inhibitors
US9062045B2 (en) 2011-09-15 2015-06-23 Novartis Ag Triazolopyridine compounds
WO2013078440A2 (en) 2011-11-23 2013-05-30 Intellikine, Llc Enhanced treatment regimens using mtor inhibitors
SG10201701343QA (en) 2012-01-26 2017-04-27 Inotek Pharmaceuticals Corp Anhydrous Polymorphs of (2r,3s,4r,5r)-5-(6-(Cyclopentylamino)-9h-Purin-9-Yl)-3,4-Dihydroxytetrahydrofuran-2-Yl) } Methyl Nitrate and Processes of Preparation Thereof
ES2894830T3 (en) 2012-04-03 2022-02-16 Novartis Ag Combination products with tyrosine kinase inhibitors and their use
WO2014152723A1 (en) 2013-03-15 2014-09-25 Inotek Pharmaceuticals Corporation Ophthalmic formulations
CA2906542A1 (en) 2013-03-15 2014-09-25 Intellikine, Llc Combination of kinase inhibitors and uses thereof
TW201605450A (en) 2013-12-03 2016-02-16 諾華公司 Combination of Mdm2 inhibitor and BRAF inhibitor and their use
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
BR112017001695A2 (en) 2014-07-31 2017-11-21 Novartis Ag combination therapy
CN109879787A (en) * 2019-01-10 2019-06-14 安徽昊帆生物有限公司 Iodo acetylthiocholine, preparation method and its application
TW202140550A (en) 2020-01-29 2021-11-01 瑞士商諾華公司 Methods of treating an inflammatory or obstructive airway disease using anti-tslp antibody

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222330A2 (en) * 1985-11-06 1987-05-20 Warner-Lambert Company N6-Substituted-5'-oxidized adenosine analogs
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
EP0277917A2 (en) * 1987-02-04 1988-08-10 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0222330A2 (en) * 1985-11-06 1987-05-20 Warner-Lambert Company N6-Substituted-5'-oxidized adenosine analogs
WO1988003147A1 (en) * 1986-10-31 1988-05-05 Warner-Lambert Company Selected n6-substituted adenosines having selective a2 binding activity
EP0277917A2 (en) * 1987-02-04 1988-08-10 Ciba-Geigy Ag Certain adenosine 5'-carboxamide derivatives

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CRISTALLI G. ET AL: "2-Alkynyl Derivatives of Adenosine and Adenosine-5'-N-ethyluronamide as Selective Agonists of A2 Adenosine Receptors", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, WASHINGTON US, pages 2363 - 2368 *
CRONSTEIN B.N.: "Adenosine, an endogenous anti-inflammatory agent", JOURNAL OF APPLIED PHYSIOLOGY, vol. 76, no. 1, pages 5 - 13 *
HUTCHINSON A.J. ET AL: "2-(Arylalkylamino)adenosine-5'-uronamides: A New Class of Highly Selective Adenosine A2 Receptor Ligands", JOURNAL OF MEDICINAL CHEMISTRY, vol. 33, WASHINGTON US, pages 1919 - 1924 *
TRIVEDI B.K. AND BRUNS R.F.: "C2,N6-Disubstituted Adenosines: Synthesis and Structure-Activity Relationships", JOURNAL OF MEDICINAL CHEMISTRY, vol. 32, WASHINGTON US, pages 1667 - 1673 *
WOLLNER A ET AL: "Acting via A2 Receptors, Adenosine Inhibits the Upregulation of Mac-1 (CD11b/CD18) Expression on FMLP-stimulated Neutrophils", AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, vol. 9, pages 179 - 185 *

Also Published As

Publication number Publication date
WO1996002553A2 (en) 1996-02-01
ZA955784B (en) 1996-08-15
GB9414193D0 (en) 1994-08-31
IL114578A0 (en) 1995-11-27
AU3698295A (en) 1996-02-16

Similar Documents

Publication Publication Date Title
WO1996002553A3 (en) AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES
JO1850B1 (en) New erythromycin derivatives their preparation process and their use as medicament
WO1996002553B1 (en) AMINO PURINE-β-D-RIBOFURANURONAMIDE DERIVATIVES
EP0430045A3 (en) Ascorbic acid tocopheryl phosphate diesters for inhibition of maillard's reaction
TW221053B (en)
ES8608487A1 (en) Benzimidazole derivatives and their thereapeutic and cosmetic use
EP1473294A3 (en) Substituted 1,3-oxathiolanes with antiviral properties
DE69021176D1 (en) Polypeptide and process for its preparation.
AU584931B2 (en) 1-``(aminoalkyl and aminoalkylamino)carbonyl and thiocarbonyl``-``,``-diarylpyrrolidine, piperidine and homopiperidineacetamides and acetonitriles
DE68923151D1 (en) Use of trifluoromethylphenyl tetrahydropyridines for the manufacture of medicaments for the treatment of anxio-depressive disorders.
IE891171L (en) 3-substituted-2-oxindole-1-carboxamides for suppressing¹t-cell function
EP0696585A4 (en)
NO307447B1 (en) Use of a pregnancy derivative
GB8720805D0 (en) 2-alkoxy-n-(1-azabicyclo(2 2 2)oct-3-yl)benzamides & thiobenzamides
ATE71092T1 (en) HYDROXYBUTENOLIDE DERIVATIVES, THEIR PREPARATION AND USE.
DE68925173D1 (en) 4-methyl and 4-ethyl substituted pyrrolidin-2-ones
EP0014981A3 (en) Medicaments and pharmaceutical compositions with cytostatic activity
AU634584B2 (en) Aroyl-ureas
HUP0001447A1 (en) Steroids substituted in position 11, method of preparation, application as medicines and pharmaceutical compositions containing them
PT90706A (en) PROCESS FOR THE PREPARATION OF DERIVATIVES OF ANTHRACICLINS PROVIDED WITH CYTOSTATIC ACTIVITY
AU2224795A (en) Ameliorant or remedy for paraneoplastic syndrome

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase